Top

Inflammopharmacology

Published in:

12-06-2023 | Celecoxib | Original Article

Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study

Authors: Kai Zhang, Xiaoyan Miao, Liqiang Jiang, Shubei Cui, Zhenwu Liu, Zhiyun Wang

Published in: Inflammopharmacology | Issue 4/2023

Abstract

Background

Imrecoxib, a novel cyclooxygenase-2 inhibitor, possesses a certain postoperative analgesic effect for several orthopedic surgeries. This multi-center, randomized, controlled, non-inferiority study intended to investigate the postoperative analgesic efficacy and safety profile of imrecoxib (versus celecoxib) in hip osteoarthritis patients undergoing total hip arthroplasty (THA).

Methods

156 hip osteoarthritis patients planned for THA were randomized into imrecoxib (N = 78) and celecoxib (N = 78) groups. Patients were orally administrated with imrecoxib or celecoxib 200 mg at 2 h (h) after THA, 200 mg every 12 h to day (D)3, and 200 mg every 24 h to D7; additionally, each patient received patient-controlled analgesia (PCA) for 2 days.

Results

Resting pain visual analogue scale (VAS) score at 6 h, 12 h, D1, D2, D3, and D7 post THA was not varied between imrecoxib and celecoxib groups (all P > 0.050), neither was moving pain VAS score (all P > 0.050). Importantly, the upper of 95% confidence interval of pain VAS score margin between imrecoxib and celecoxib groups was within the non-inferiority threshold (Δ = 1.0), indicating the fact that non-inferiority was established. The additional and total consumption of PCA was not varied between imrecoxib and celecoxib groups (both P > 0.050). Also, no difference was seen in Harris hip score, European Quality of Life 5-Dimensions (EQ-5D) total and VAS scores at month (M)1, M3 between the two groups (all P > 0.050). Besides, the incidences of all adverse events were not different between imrecoxib and celecoxib groups (all P > 0.050).

Conclusion

Imrecoxib is non-inferior to celecoxib for postoperative analgesia in hip osteoarthritis patients undergoing THA.

Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K (2022) Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med Chem 13:471–496. https://doi.org/10.1039/d1md00280eCrossRefPubMedPubMedCentral

Anger M et al (2021) PROSPECT guideline for total hip arthroplasty: a systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia 76:1082–1097. https://doi.org/10.1111/anae.15498CrossRefPubMed

Aresti N, Kassam J, Nicholas N, Achan P (2016) Hip osteoarthritis. BMJ 354:i3405. https://doi.org/10.1136/bmj.i3405CrossRefPubMed

Beverly A, Kaye AD, Ljungqvist O, Urman RD (2017) Essential elements of multimodal analgesia in enhanced recovery after surgery (ERAS) guidelines. Anesthesiol Clin 35:e115–e143. https://doi.org/10.1016/j.anclin.2017.01.018CrossRefPubMed

Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF (2004) Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin 25:927–931PubMed

Derry S, Moore RA (2012) Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 3:CD004233. https://doi.org/10.1002/14651858.CD004233.pub3CrossRefPubMed

Ferguson RJ, Palmer AJ, Taylor A, Porter ML, Malchau H, Glyn-Jones S (2018) Hip replacement. Lancet 392:1662–1671. https://doi.org/10.1016/S0140-6736(18)31777-XCrossRefPubMed

Fu M, Zhou H, Li Y, Jin H, Liu X (2022) Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study. Arthritis Res Ther 24:8. https://doi.org/10.1186/s13075-021-02705-6CrossRefPubMedPubMedCentral

Gao GM et al (2017) The efficacy of Imrecoxib and celecoxib in axial spondyloarthritis and their influence on serum Dickopff-Related protein 1 (DKK-1) levels. Med Sci Monit 23:2985–2992. https://doi.org/10.12659/msm.901727CrossRefPubMedPubMedCentral

Goh SL et al (2019) Relative efficacy of different exercises for pain, function, performance and quality of life in knee and hip osteoarthritis: systematic review and network meta-analysis. Sports Med 49:743–761. https://doi.org/10.1007/s40279-019-01082-0CrossRefPubMedPubMedCentral

Goodman SM et al (2017) 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol 69:1538–1551. https://doi.org/10.1002/art.40149CrossRefPubMed

Guo W, Liu Y, Li J (2022) Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study. Inflammopharmacology 30:875–881. https://doi.org/10.1007/s10787-022-00938-8CrossRefPubMed

Guo Y, Jiang D, Mai Z, Chen Y, Li T, Gao G (2023) Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. Clin Rheumatol. https://doi.org/10.1007/s10067-023-06541-8CrossRefPubMed

Jiang M, Deng H, Chen X, Lin Y, Xie X, Bo Z (2020) The efficacy and safety of selective COX-2 inhibitors for postoperative pain management in patients after total knee/hip arthroplasty: a meta-analysis. J Orthop Surg Res 15:39. https://doi.org/10.1186/s13018-020-1569-zCrossRefPubMedPubMedCentral

Jiang Y et al (2021) Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial. Ann Transl Med 9:469. https://doi.org/10.21037/atm-21-264CrossRefPubMedPubMedCentral

Ju Z, Li M, Xu J, Howell DC, Li Z, Chen FE (2022) Recent development on COX-2 inhibitors as promising anti-inflammatory agents: the past 10 years. Acta Pharm Sin B 12:2790–2807. https://doi.org/10.1016/j.apsb.2022.01.002CrossRefPubMedPubMedCentral

Katz JN, Arant KR, Loeser RF (2021) Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA 325:568–578. https://doi.org/10.1001/jama.2020.22171CrossRefPubMedPubMedCentral

Meng Q et al (2021) The prescription patterns and safety profiles of oral non-steroidal anti-inflammatory drugs in China: an 8-year real-life analysis. Ann Palliat Med 10:2224–2237. https://doi.org/10.21037/apm-20-2356CrossRefPubMed

Nilsdotter A, Bremander A (2011) Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons (AAOS) hip and knee questionnaire. Arthritis Care Res (hoboken) 63(Suppl 11):S200-207. https://doi.org/10.1002/acr.20549CrossRefPubMed

Oemar M, Oppe M (2013) EQ-5D-3L User Guide. Basic information on how to use the EQ-5D-3L instrument. . EuroQol Group

Phillips RE (2021) Review of hip and knee osteoarthritis. JAMA 325:2504–2505. https://doi.org/10.1001/jama.2021.6018CrossRefPubMed

Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P (2017) Celecoxib for osteoarthritis. Cochrane Database Syst Rev 5:CD009865. https://doi.org/10.1002/14651858.CD009865.pub2CrossRefPubMed

Sun X et al (2021) Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis. Ann Transl Med 9:575. https://doi.org/10.21037/atm-21-290CrossRefPubMedPubMedCentral

Tang C et al (2019) Cerebral mechanism of celecoxib for treating knee pain: study protocol for a randomized controlled parallel trial. Trials 20:58. https://doi.org/10.1186/s13063-018-3111-8CrossRefPubMedPubMedCentral

Vos T et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2CrossRefPubMedPubMedCentral

Wainwright TW et al (2020) Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations. Acta Orthop 91:3–19. https://doi.org/10.1080/17453674.2019.1683790CrossRefPubMed

Yang L, Shen Q, Hu C, Wang Y, Zhu X, Shu S, Luo Z (2022) Comparative pharmacokinetics and safety of imrecoxib, a novel selective cyclooxygenase-2 inhibitor, in elderly healthy subjects. Drug Des Devel Ther 16:3865–3876. https://doi.org/10.2147/DDDT.S387508CrossRefPubMedPubMedCentral

Zong HX et al (2022) A real-world study on the effect of imrecoxib for patients with axial spondyloarthritis. Drug Des Devel Ther 16:2755–2765. https://doi.org/10.2147/DDDT.S376406CrossRefPubMedPubMedCentral

Title: Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study
Authors: Kai Zhang
Xiaoyan Miao
Liqiang Jiang
Shubei Cui
Zhenwu Liu
Zhiyun Wang
Publication date: 12-06-2023
Publisher: Springer International Publishing
Keywords: Celecoxib
Osteoarthritis of the Hip
Osteoarthritis of the Hip
Analgesics in Dentistry
Hip-TEP
Hip-TEP
Published in: Inflammopharmacology / Issue 4/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01260-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2023

Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury

Fractionated whole body γ-irradiation aggravates arthritic severity via boosting NLRP3 and RANKL expression in adjuvant-induced arthritis model: the mitigative potential of ebselen

The NLRP3 inflammasome: role in the pathobiology of chronic pain

The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)

Effect of ethyl gallate and propyl gallate on dextran sulfate sodium (DSS)-induced ulcerative colitis in C57BL/6 J mice: preventive and protective

Umbelliferon: a review of its pharmacology, toxicity and pharmacokinetics